证券代码：000908 证券简称：*ST景峰 公告编号：2025-080 湖南景峰医药股份有限公司 第八届董事会第四十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、湖南景峰医药股份有限公司（以下简称"公司"）于2025年10月17日以电子 邮件、电话、即时通讯等方式发出了关于召开第八届董事会第四十三次会议的通知。 2、公司第八届董事会第四十三次会议于2025年10月27日上午9:00-11:00以通 讯方式召开。 3、会议应参加表决董事8人，实际参与表决董事8人。 4、会议由代行董事长张莉女士主持，公司监事及高级管理人员列席了会议。 5、本次会议的通知、召集、召开、审议、表决程序均符合法律、行政法规、部 门规章、规范性文件和《公司章程》的规定，会议形成的决议合法、有效。 二、董事会会议审议情况 具体内容详见公司同日在巨潮资讯网站披露的《2025年第三季度报告》（公告 编号：2025-081）。 表决结果：8票同意，0票反对，0票弃权。 2、《关于提名公司第八届董事会非独立董事候选人的议案》； 经公司董事会提名委员 ...

湖南景峰医药股份有限公司 股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 1、湖南景峰医药股份有限公司（以下简称"公司"）于 2025 年 10 月 21 日收到湖南省常德市中级人民法院（以下简称"常德中院"）送达的（2024） 湘 07 破申 7 号《民事裁定书》和（2025）湘 07 破 15 号《决定书》，裁定受 理彭东钜、上海鑫绰投资管理有限公司对公司的重整申请，并指定北京市中伦 律师事务所担任公司管理人。 2、常德中院已裁定公司进入重整程序，公司可能存在因重整失败而被宣 告破产的风险。如果法院裁定公司破产，公司将被实施破产清算，根据《深圳 证券交易所股票上市规则》（以下简称《股票上市规则》）第 9.4.18 条第 （八）项的规定，公司股票将面临被终止上市的风险。 证券代码：000908 证券简称：*ST 景峰 公告编号：2025-084 3、公司最近三个会计年度扣除非经常性损益前后净利润孰低者均为负值， 同时，大信会计师事务所（特殊普通合伙）（以下简称"大信"）对公司 2024 年度财务报告出具了带持续经营相关 ...

2025 年 10 月 27 日，公司收到湖南省常德市中级人民法院（以下简称"常德中 院"或者"法院"）送达的《决定书》[（2025）湘 07 破 15 号之一]，准许公司在 管理人的监督下自行管理财产和营业事务。根据《股票上市规则》及《深圳证券交 易所上市公司自律监管指引第 14 号——破产重整等事项》等相关规定，现将相关情 况公告如下： 一、《决定书》主要内容 2025 年 10 月 23 日，景峰医药向法院提出申请，请求法院许可其在重整期间在 管理人监督下自行管理财产和营业事务。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 湖南景峰医药股份有限公司（以下简称"景峰医药"或者"公司"）重整工作 正有序推进中，如公司顺利实施重整并执行完毕重整计划，将有利于化解债务风险， 有利于优化公司资产负债结构，提升公司的持续经营和盈利能力。如果公司未能顺 利实施重整或执行完毕重整计划，公司仍存在因重整失败而被宣告破产的风险。如 果公司被宣告破产，根据《深圳证券交易所股票上市规则》（以下简称《股票上市 规则》）的相关规定，公司股票将面临被终止上市的风险。 ...

关于法院许可公司在重整期间继续营业的公告 证券代码：000908 证券简称：*ST景峰 公告编号：2025-079 湖南景峰医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 2、公司 2022 年度、2023 年度及 2024 年度扣除非经常性损益前后净利润孰低者 均为负值，同时，大信会计师事务所（特殊普通合伙）对公司 2024 年度财务报告出 具了带持续经营相关重大不确定性段落的无保留意见审计报告，公司存在触及《股 票上市规则》第 9.8.1 条第（七）项规定的被实施其他风险警示的情形，截至本公 告披露日，《2024 年年度审计报告》中"与持续经营相关的重大不确定性"段落涉 及事项的影响暂未消除。 根据《股票上市规则》的相关规定，法院已裁定受理申请人提出的重整申请， 公司股票交易已被深圳证券交易所实施退市风险警示。 3、如果公司顺利实施重整并执行完毕重整计划，将有利于改善公司的资产负债 结构，推动公司回归可持续发展轨道。若重整失败，公司将存在被法院裁定破产的 风险。如果公司被法院裁定破产，根据《股票上市规则》的相关规定，公司股票将 ...

Market Overview - As of October 27, the Shanghai Composite Index rose by 1.18%, closing at 3996.9445 points, while the Shenzhen Component Index increased by 1.51%, closing at 13489.403 points [1]. Top Gainers in Hunan Stocks - *ST Jingfeng opened at 7.690 and closed at 7.690, with a daily increase of 5.05%, maintaining the same price throughout the day, with a trading volume of 24,128 lots [2]. - Tianqiao Crane opened at 4.210 and closed at 4.340, rising by 4.08%, with a daily high of 4.350 and a low of 4.150, and a trading volume of 1,184,114 lots [2]. - Aoshikang opened at 39.620 and closed at 40.920, up by 3.52%, reaching a high of 41.240 and a low of 39.600, with a trading volume of 62,736 lots [2]. - Yanjinpuzi opened at 69.010 and closed at 70.350, increasing by 3.30%, with a daily high of 71.120 and a low of 68.500, and a trading volume of 36,492 lots [2]. - Hualing Steel opened at 5.740 and closed at 5.910, up by 2.96%, with a high of 5.970 and a low of 5.740, and a trading volume of 1,103,156 lots [2]. Top Losers in Hunan Stocks - Hengli Tui opened at 0.160 and closed at 0.150, experiencing a decline of 11.76%, with a daily high of 0.170 and a low of 0.150, and a trading volume of 611,606 lots [3]. - *ST Gaosi opened at 8.300 and closed at 8.350, down by 2.45%, with a high of 8.450 and a low of 8.130, and a trading volume of 58,408 lots [3]. - Changlan Technology opened at 17.700 and closed at 17.410, decreasing by 1.97%, with a high of 17.780 and a low of 17.200, and a trading volume of 45,737 lots [3]. - Hansen Pharmaceutical opened at 6.620 and closed at 6.510, down by 1.06%, with a high of 6.620 and a low of 6.480, and a trading volume of 94,306 lots [3]. - Hunan Investment opened at 5.730 and closed at 5.630, decreasing by 1.05%, with a high of 5.740 and a low of 5.580, and a trading volume of 171,054 lots [3].

Core Viewpoint - ST Jinfeng officially entered judicial reorganization on October 21, becoming the seventh A-share company to obtain a "reorganization road sign" this year. Despite the cash injection of 526 million yuan from Shiyao Group and 122 million yuan from German state-owned enterprises, the company still faces significant operational, financial, governance, and integration risks [1] Financial Challenges - ST Jinfeng's ability to continue operations is in doubt, with a net profit loss of 76.12 million yuan and a high debt-to-asset ratio of 101.61%. The company has incurred cumulative losses of nearly 2.4 billion yuan since 2019, leading to liquidity crises and bankruptcy pre-reorganization applications [2] Uncertainties in Reorganization - The reorganization process faces multiple challenges, including the difficulty of implementing the reorganization plan submitted by Shiyao, the need for creditor support, and the complexities of asset separation and injection. Additionally, the recovery of core assets and the integration of new management may impact operational stability [3] Business Decline and Product Risks - ST Jinfeng's main business has significantly declined, with injection drug revenue dropping over 70% since its core products were excluded from the national medical insurance catalog in 2019. The company has not established alternative product lines, leaving it vulnerable to market pressures [4] Asset Disposal and Related Party Transactions - Prior to reorganization, ST Jinfeng's subsidiary, Dalian Dezhe, engaged in profit distribution, capital reduction, and asset repurchase, raising concerns about the fairness of these transactions and potential harm to the overall interests of the listed company [5] Conclusion on Reorganization - Obtaining the "reorganization road sign" is just the beginning of ST Jinfeng's challenges. While the entry of Shiyao Group brings capital and resources, the company must address business recovery, debt resolution, governance integration, and market trust rebuilding to achieve a true turnaround [6]

Core Viewpoint - *ST Jingfeng's stock reached the daily limit with a price of 7.05 yuan, reflecting a 5.02% increase, driven by restructuring progress, debt waiver, and successful bids in centralized procurement [1][2]. Company Summary - The company is currently in a transitional phase of restructuring, with Shiyao Group confirmed as the lead investor and a restructuring investment agreement signed, providing hope for the company's future [2]. - Five fund managers waived 110 million yuan in principal and related fees, significantly reducing the company's debt burden, which has boosted market confidence in its future development [2]. - The sale of the "Taihu Star" asset recovered 64.6928 million yuan, helping to optimize the asset structure by divesting loss-making subsidiaries [2]. - The company has successfully won bids for products like sodium hyaluronate injection in several provincial alliances, which is expected to expand market share and improve performance [2]. - In the first half of 2025, the company maintained a certain level of R&D investment and received government subsidies, providing support for its performance [2]. Industry Summary - The pharmaceutical industry has recently attracted market attention, with several stocks in the sector performing actively on October 24, 2025, contributing to *ST Jingfeng's stock limit-up [2]. - Technical indicators suggest that if the MACD forms a golden cross, it could further support the stock price's upward movement [2]. - There may have been capital inflows on the day of the stock limit-up, and it is important to monitor whether this trend continues [2].

证券代码：000908 证券简称：*ST 景峰 公告编号：2025-077 湖南景峰医药股份有限公司 关于股东部分股份冻结变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，湖南景峰医药股份有限公司（以下简称"公司"）通过查询中国证券登 记结算有限责任公司系统，获悉公司控股股东叶湘武先生所持公司的部分股份存在 解除司法冻结及轮候冻结生效的情况，现将具体情况公告如下： 二、控股股东累计被司法冻结及司法再冻结的情况 截至本公告披露日，叶湘武先生及其一致行动人所持股份累计被冻结及司法再 冻结等情况如下： | 股东名称 | 持股数量 | 持股比例 | 累计被冻结 | 占其所持股 | | 占公司总股 | 冻结类型 | | --- | --- | --- | --- | --- | --- | --- | --- | | | （股） | | 数量（股） | 份比例 | | 本比例 | | | 叶湘武 | 112,252,286 | 12.76% | 4,161,400 | | 3.70% | 0.47% | 司法冻结 | | | | | 20,189,242 ...

Core Viewpoint - ST Jingfeng's capital fate has reached a critical turning point as the Hunan Changde Intermediate People's Court has officially accepted creditors' restructuring applications, marking a significant step in the company's efforts to survive amidst financial difficulties [2][8]. Group 1: Company Background and Financial Performance - ST Jingfeng, originally a subsidiary of Yibai Pharmaceutical, once thrived with peak sales exceeding 1 billion yuan, particularly driven by its core product, the Ginkgo Biloba Glucose Injection [3]. - The company experienced a dramatic decline in revenue starting in 2019, with a nearly 50% drop in operating income and over 70% decline in injection product revenue, leading to continuous losses over five years [5]. - Cumulatively, from 2019 to 2023, ST Jingfeng reported losses of nearly 2.4 billion yuan, with a skyrocketing asset-liability ratio of 114.49% by the end of 2023, indicating a severe liquidity crisis [6]. Group 2: Stock Market Performance - Despite its poor financial performance, ST Jingfeng's stock exhibited extreme volatility, achieving 46 trading limits in 54 days from July 2 to September 13, 2024, with a cumulative increase of over 500% during this period [7][8]. Group 3: Restructuring Process - The court's acceptance of the restructuring application signifies the transition from a year-long pre-restructuring phase to a substantive restructuring process, making ST Jingfeng the seventh A-share company to receive a restructuring approval in 2024 [8]. - The restructuring plan involves Shiyao Group investing 526 million yuan for controlling stakes, with an additional 122 million yuan from a local state-owned platform, totaling 648 million yuan [9]. Group 4: Strategic Implications for Shiyao Group - Shiyao Group's involvement as the lead investor in the restructuring is pivotal, as it aims to enhance its oncology product pipeline, which has faced declining sales in recent years [10][11]. - The acquisition of ST Jingfeng's assets, particularly in the field of anti-tumor plant drugs, is expected to fill gaps in Shiyao Group's product matrix and strengthen its market position [11][12].

证券代码：000908 证券简称：*ST景峰 公告编号：2025-076 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 湖南景峰医药股份有限公司（以下简称"景峰医药"或者"公司"）于 2025 年 10 月 21 日收到湖南省常德市中级人民法院（以下简称"常德中院"或者"法院"） 送达的（2024）湘 07 破申 7 号《民事裁定书》和（2025）湘 07 破 15 号《决定书》， 裁定受理彭东钜、上海鑫绰投资管理有限公司（以下统称"申请人"）对公司的重 整申请，并指定北京市中伦律师事务所担任公司管理人。详见公司于同日披露的《关 于法院裁定受理公司重整并指定管理人及公司股票交易将被实施退市风险警示暨公 司股票停复牌并变更证券简称的公告》（公告编号：2025-075）。 公司债权人应在 2025 年 11 月 23 日（含当日）前向管理人申报债权，并提供相 关证据材料。债权人在预重整期间进行的债权申报继续有效，无需再行申报。 管理人将根据相关法律法规开展公司重整相关工作，通知各债权人及时申报债 权并参加债权人会议。现将具体情况通知如下： 一、债 ...